Immunovant (IMVT) Gets a Buy From Piper Sandler
TipRanksApr 26 07:52 ET
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Yahoo FinanceApr 22 11:53 ET
Don't Ignore The Insider Selling In Immunovant
We wouldn't blame Immunovant, Inc. (NASDAQ:IMVT) shareholders if they were a little worried about the fact that Peter Salzmann, the CEO & Director recently netted about US$990k selling shares at an av
Simply Wall StApr 22 06:00 ET
Buy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy Confidence
TipRanksApr 22 05:55 ET
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing
Peter Salzmann, Director, Chief Executive Officer, on April 17, 2024, sold 34,079 shares in Immunovant (IMVT) for $990,269. Following the Form 4 filing with the SEC, Salzmann has control over a total
MT NewswiresApr 19 18:01 ET
What Makes Immunovant (IMVT) a New Buy Stock
Yahoo FinanceApr 17 12:00 ET
Immunovant Initiated at Outperform by Oppenheimer
Immunovant Initiated at Outperform by Oppenheimer
Dow JonesMar 28 06:59 ET
Express News | Oppenheimer Initiates Coverage On Immunovant With Outperform Rating, Announces Price Target of $50
Moomoo 24/7Mar 28 06:49 ET
Express News | Truist Securities Reiterates Buy on Immunovant, Maintains $48 Price Target
Moomoo 24/7Mar 25 12:11 ET
Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials
TipRanksMar 21 13:15 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
BenzingaMar 21 09:05 ET
11 Oversold Biotech Stocks To Buy Right Now
Yahoo FinanceMar 17 17:20 ET
Immunovant Initiated at Buy by Goldman Sachs
Immunovant Initiated at Buy by Goldman Sachs
Dow JonesMar 13 08:48 ET
Express News | Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50
Moomoo 24/7Mar 13 08:38 ET
Immunovant Inc.: A Strong Buy on IMVT-1402's Market Potential and Upcoming Clinical Catalysts
TipRanksMar 13 05:25 ET
Express News | Immunovant Awarded U.S. Patent for IMVT-1402
Moomoo 24/7Mar 12 07:32 ET
Wells Fargo Screens for Momentum Names to Play and Contrarian Plays to Avoid
Seeking AlphaMar 4 10:02 ET
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares
Yahoo FinanceFeb 23 23:22 ET
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing
Peter Salzmann, Director, Chief Executive Officer, on February 22, 2024, sold 13,454 shares in Immunovant (IMVT) for $486,362. Following the Form 4 filing with the SEC, Salzmann has control over a tot
MT NewswiresFeb 23 16:18 ET
S&P 500 Futures Decline In Premarket Trading; Discover Finl Svcs, GlobalFoundries Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Discover Financial Services (DFS) was up 14.9% in p
Dow JonesFeb 20 07:31 ET
No Data
No Data